Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Pleural Effusions

NCT03869697 is registered in ClinicalTrials.gov with Clover Biopharmaceuticals AUS Pty as lead sponsor.

NCT NCT03869697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03869697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Pleural Effusions
Lead sponsor
Clover Biopharmaceuticals AUS Pty
Phase
Phase 1
Overall status
Completed
Start date
November 20, 2019
Completion date
November 23, 2021
Enrollment
5 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural effusions